Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms (CAMELLIA)

  • STATUS
    Recruiting
  • End date
    Apr 14, 2024
  • participants needed
    605
  • sponsor
    MelanomaPRO, Russia
Send
Updated on 14 June 2022
See if I qualify
skin lesion
skin tumor

Summary

A Multicenter, Prospective, Low-interventional Clinical Study Evaluating on mobile application validation ("ProRodinki") in assessing the risk of skin malignant neoplasms

Description

This is a multicentre, low-intervention, prospective study. In several centers, patients will be selected into 4 cohorts:

  1. Patients with complaints of skin neoplasm(s) who have sought the help of a specialist to remove it(them), and patients with an established clinical diagnosis of suspicious/doubtful skin neoplasm(s) who are scheduled to undergo excisional biopsy to verify the diagnosis;
  2. Patients who have complaints about a skin neoplasm(s) and consider it (them) suspicious without using the ProRodinki application and who have asked for help from a specialist in order to remove it(them);
  3. patients who have complaints about skin neoplasm(s) and who, using the ProRodinki application, received a response that the neoplasm(s) is (are) suspicious / doubtful (s), and sought help from a specialist in order to remove it (their) to verify the diagnosis;
  4. Cohort 4 (prospective): patients with suspicious/doubtful skin neoplasm(s) detected during an objective examination by a specialist without using the ProRodinki application, and who are scheduled for an excisional biopsy to verify the diagnosis .

Patients scheduled for excisional biopsy of skin lesion(s) will be invited to participate in this study. After signing the informed voluntary consent form in the ProRodinki application, an account will be created for the patient, in which a questionnaire will be filled out, photo-documentation of the skin neoplasm(s) will be performed, and the generated report will be sent for evaluation by artificial intelligence. The response received from the application for each clinical case will be recorded and all neoplasms will be grouped according to the classification of the application. Following this procedure, an excisional biopsy of the lesion(s) will be scheduled. From the moment of inclusion in the study until the excisional biopsy, an interval of no more than 2-4 weeks is allowed. Immediately before the excisional biopsy procedure, other non-invasive instrumental examinations (dermatoscopy, digital dermatoscopy) will be performed. After excisional biopsy of the skin neoplasm(s), a routine intravital pathological examination with hematoxylin and eosin staining will be performed, if necessary, immunohistochemical and molecular genetic tests will be performed. The selected biosamples (paraffin blocks) will then be analyzed centrally by a morphologist. All neoplasms will be classified according to the MPATH-Dx classification, the 2018 WHO classification of skin tumors, and will be assigned an ICD-O-3 code. For invasive melanomas, the characteristics necessary to establish the morphological stage of pT will also be collected (see also the Study Procedures section). The conclusion of the intravital pathoanatomical examination will be photo-documented through the ProRodinki application and attached to the patient's account in the tab where the photo of the removed neoplasm is stored.

Details
Condition Melanoma (Skin), Nevus, Nevus, Spitz, Nevus Halo, Nevus, Pigmented, Basal Cell Carcinoma, Squamous Cell Carcinoma, Bowen's Disease, Melanoma in Situ, Spot Pigmented
Treatment Mobile phone application "ProRodinki"
Clinical Study IdentifierNCT05402046
SponsorMelanomaPRO, Russia
Last Modified on14 June 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

General (for all cohorts)
Signed informed consent form for participation in the study
Age of the patient over 18 years of age at the time of inclusion in the study (at the time of signing the consent form)
The patient is scheduled for an incisional/excisional biopsy (or wide excision) of the skin lesion(s) within 2-4 weeks from entry into the study and the patient is able to tolerate this intervention
Cohort 1 (prospective): Patients complaining of a skin lesion(s) who sought specialist help
to remove it(s) and patients with a clinical diagnosis of suspicious/doubtful skin
lesion(s) who are scheduled for excisional biopsy to verify the diagnosis
Patients who have complaints about skin neoplasm(s) and who have sought the physician
to remove it(them)
Clinically suspicious/doubtful skin neoplasm(s) detected during an objective
examination by a dermatologist or oncologist without the use of instrumental
diagnostic methods
Cohort 2 (prospective): Patients who complain of a skin neoplasm(s) and consider it(them)
suspicious without using the ProRodinki application and seek specialist help to remove
it(them)
Patients who have complaints about a skin neoplasm(s) and consider it (them)
suspicious without using the ProRodinki application and who have asked a physician to
remove it(them)
Clinically suspicious/doubtful skin neoplasm(s) detected during an objective
examination by the patient without using the ProRodinki application
Cohort 3 (prospective): patients who complained of skin neoplasm(s) and who, using the
ProRodinki application, received an answer that the neoplasm(s) is (are)
suspicious/doubtful(s), and applied for help from a specialist in order to remove it
(their) to verify the diagnosis
Patients who have complaints about skin neoplasm(s), and who, using the ProRodinki
application, received a response that the neoplasm(s) is (are) suspicious / doubtful
(s), and referred to the physician to remove it (their) to verify the diagnosis
Clinically suspicious/doubtful skin neoplasm(s) detected by the patient when using the
ProRodinki application
Cohort 4 (prospective): patients with suspicious/doubtful skin neoplasm(s) detected during
an objective examination by a specialist without using the ProRodinki app, and who are
scheduled for an excisional biopsy to verify the diagnosis
Patients who have a suspicious/dubious skin neoplasm(s) detected during an objective
examination by a specialist without using the ProRodinki application, and who are
scheduled to undergo an excisional biopsy to verify the diagnosis
Clinically suspicious(s)/doubtful(s) skin neoplasm(s) detected during an objective
examination by a dermatologist or oncologist without the use of instrumental
diagnostic methods and the ProRodinki application

Exclusion Criteria

General (all cohorts)
Patient is NOT scheduled for excisional biopsy (or wide excision) of skin lesion(s)
within 3 months of enrollment in the study OR the patient is unable to tolerate this
intervention
Available intravital pathological confirmation of the nature of the neoplasm(s)
(benign or malignant) that(s) are planned to be removed as part of this study
Neoplasm(s) located subcutaneously or in soft tissues and, according to clinical
signs, having no connection with the skin
Allergic reaction to drugs used during incisional / excisional biopsy or wide
excision
The patient's inability to follow study procedures (including contact with the
investigator during observation visits) or other reasons that, in the opinion of the
principal investigator, may become an obstacle to the patient's participation in the
study
For the period of inclusion in the study, do not sign the informed consent form
The age of the patient is younger than 18 years
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

skin lesion
skin tumor

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note